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Abstract
Background: Estimates of the burden of antimicrobial resistance (AMR) are needed to ascertain AMR impact, to
evaluate interventions, and to allocate resources efficiently. Recent studies have estimated health, cost, and economic
burden relating to AMR, with outcomes of interest ranging from drug-bug resistance impact on mortality in a hospital
setting to total economic impact of AMR on the global economy. However, recent collation of this information has
been largely informal, with no formal quality assessment of the current evidence base (e.g. with predefined checklists).
This review therefore aims to establish what perspectives and resulting methodologies have been used in establishing
the burden of AMR, whilst also ascertaining the quality of these studies.
Methods: The literature review will identify relevant literature using a systematic review methodology. MEDLINE,
EMBASE, Scopus and EconLit will be searched utilising a predefined search string. Grey literature will be identified by
searching within a predefined list of organisational websites. Independent screening of retrievals will be performed in a
two-stage process (abstracts and full texts), utilising a pre-defined inclusion and exclusion criteria. Data will be
extracted into a data extraction table and descriptive examination will be performed. Study quality will be assessed
using the Newcastle-Ottawa scales and the Philips checklists where appropriate. A narrative synthesis of the results will
be presented.
Discussion: This review will provide an overview of previous health, cost and economic definitions of burden and
the resultant impact of these different definitions on the burden of AMR estimated. The review will also explore
the methods that have been used to calculate this burden and discuss resulting study quality. This review can
therefore act as a guide to methods for future research in this area.
Systematic review registration: PROSPERO CRD42016037510
Keywords: Antimicrobial resistance, Burden, Methods, Systematic review
Background
Antimicrobial resistance (AMR) can be defined as the
phenomenon in which microorganisms persist in the pres-
ence of antimicrobials, which are commonly used to pre-
vent and/or treat infectious disease. AMR is a cause for
concern within the UK and globally, due to the current
and great potential negative impact on population health
[1, 2]. AMR-associated burden can be defined as AMR
impact on health (mortality or morbidity), impact on
healthcare and patient costs or impact on the economy
(labour force impact, productivity impact or opportunity
cost) depending on study perspective. The AMR review,
chaired by Jim O’Neill, has recently published estimates of
potential future AMR burden, for example stating global
gross domestic product (GDP) loss over the next 40 years
could be as great as $3 trillion [1]. These estimates have
since been cited by policy makers and the media [3, 4],
showing the demand for estimates quantifying the
current and potential future problem AMR poses.
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Accurate estimates of disease-related burden are needed
for policy makers to establish disease-related resource
need and advocate for appropriate levels of funding and
are critical inputs for any health economic evaluations of
AMR interventions.
Recent descriptive review articles have discussed methods
of burden estimation in the context of AMR, citing a few
articles as examples of different methodologies [5–7]. How-
ever, since the 2012 rapid review update of a previous sys-
tematic review [8, 9], there has been no systematic review
which looks into the estimation of burden associated with
AMR. None of the aforementioned reviews formally quality
assess study methodology, which is needed to highlight
methodological issues in establishing the burden of AMR.
The 2012 rapid review by Smith and Coast [8] concluded
that the evidence base suggests the burden of AMR is rela-
tively modest due to the narrow perspective taken by most
studies, and that a wider societal perspective was needed to
capture the true impact. However, with more recent work
taking a wider perspective on AMR burden [1] and many
more research articles being published in this area in recent
years, a new assessment is required of the current estimates
of both health and economic AMR burden.
The aims of this systematic review include the following:
(i) to establish what perspectives and resulting methodolo-
gies have been used in establishing the burden of AMR,
(ii) to see how this impacts on the burden estimates given
and (iii) to assess the quality of these studies.
Methods/design
Research question
What perspectives and resulting methodologies have
been used in establishing the burden of AMR?
Study overview
Figure 1 depicts an overview of the study procedure.
Study eligibility
Any studies that aim to quantify the burden of AMR
within humans will be considered in this review, and
this includes studies across any microbes, infections
and country settings.
The modified PICO [10] inclusion and exclusion criteria
to be applied at the review stages can be found in Table 1.
Search strategy
The methods used in this systematic review are in line with
the PRISMA guidelines [11]. In line with previous pub-
lished protocols [12], a completed copy of the PRISMA-P
checklist has been completed (see Additional file 1).
The search period will be restricted from 2013 on-
wards; this date was chosen to avoid retrieval duplication
with Smith and Coast [8]. Ovid “Medline and EMBASE”,
Scopus and EconLit will be searched, along with grey
literature from predetermined agency websites. The
following agency websites were defined after consult-
ing a group of AMR researchers. Their content will be
Fig. 1 Overview of study methodology
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searched for reports and articles relating to the popu-
lation of interest:
 Public Health England
 Public Health Wales
 Health Protection Scotland
 NHS Health Scotland
 Department of Health (UK)
 Health Protection Agency
 National Institute for Health and Care Excellence
 Centers for Disease Control and Prevention
 World Health Organisation
 European Commission for Public Health
 Review on Antimicrobial Resistance
It has been previously stated that many papers do not
mention AMR generally, but rather specific microbes
[8]. In an attempt to tackle this, an additional 13
clinically relevant bacteria will be highlighted in the
search. These can be identified in the stated search
string below (note that this is in the format for Scopus,
the same terms are to be reformatted for OVID and
EconLit searches):
((TITLE ((excess OR associated OR attributable) W/2
(burden OR morbidity OR mortality OR cost*)) OR ABS
((excess OR associated OR attributable) W/2 (burden OR
morbidity OR mortality OR cost*))) OR (TITLE ((eco-
nomic OR clinical OR global) W/2 (impact OR outcome*
OR burden OR cost*)) OR ABS ((economic OR clinical
OR global) W/2 (impact OR outcome* OR burden OR
cost*)))) AND ((ALL ((“antibiotic” OR “antimicrobial” OR
“multidrug” OR “microbial-drug”) PRE/1 resistan*)) OR
((TITLE (enterococc* OR escherichia OR streptococc* OR
staphylococc* OR klebsiealla OR pseudomonas OR neis-
seria OR chlamydia OR clostridi* OR mycobacteri* OR
“gram-positive” OR “gram-negative”) OR ABS (enterococc*
Table 1 Inclusion/exclusion criteria
Criteria Inclusion Exclusion
Population Humans Animals
All ages Plants
All sexes
Infection with antimicrobial resistant organism
Intervention Not applicable Not applicable
Comparator Not applicable Not applicable
Outcomes Associated health burden, to include but not
restricted to:
Morbidity; for example excess length of stay
in hospital
Mortality
Health-related quality of life only
Associated Healthcare cost burden, to include
but not restricted to:
Resource use
Opportunity cost
Molecular biology only
Economic burden, to include but not
restricted to:
Costs associated with loss of productivity and
reduced labour force
Work-loss hours per/case episode
Epidemiology only
Secondary burden from not being able to use
antibiotics in ways previously or currently used in
healthcare, to include but not restricted to:
Reduced surgery Reduced use in chemotherapy
and similar therapies
Outcomes associated with the evaluation of
an intervention such as clinical cure rate only
Study design Case–control studies Editorials
Cohort studies Letters
Cross–sectional studies Case series report
Longitudinal studies Conference abstracts/reports
Randomised controlled trials Evaluations of treatments/interventions
Modelling studies Reviews
Economic evaluations
Other English language
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OR escherichia OR streptococc* OR staphylococc* OR
klebsiealla OR pseudomonas OR neisseria OR chla-
mydia OR clostridia* OR mycobacteri* OR “gram-posi-
tive” OR “gram-negative”)) AND ((TITLE (susceptib*
OR nonsusceptib* OR resistan*) OR ABS (susceptib*
OR nonsusceptib* OR resistan*)) OR (ALL ((“antibiotic”
OR “antimicrobial” OR “multidrug” OR “microbial-drug”)
PRE/1 resistan*)))))
The lead reviewer (NN) will review all abstracts and
full texts. Independent reviewers will perform a parallel
review of the abstracts and full texts, with each of these
reviewers being assigned a percentage of the total retrieval
items. Any discrepancies will be discussed and re-
examined until agreement is reached.
Quality assessment
Risk of bias in individual studies will be assessed using
the Newcastle-Ottowa scales for cohort and case control
studies [13], whilst the Philips checklist will be used for
economic models [14]. These tools were chosen as the
focus of this review is on study methodology rather than
reporting standards.
Risk of bias across studies will be assessed in two
groups; studies looking at health burden and studies
looking at all other burden, and will simply be assessed
based on the sign and significance of the outcome. This
is due to the expected heterogeneity in studies (outcome,
infection, resistance).
Data collection and analysis
Data will be collected by the lead reviewer (NN). Data
will be inputted into a standardised data extraction table
(Excel) and independently checked to ensure quality.
The following information will be extracted: study
identifiers, study characteristics (perspective, country
setting), population characteristics, data setting (hospital
or community), study methodology, outcome of interest
(mortality, length of stay, cost), results (e.g. resistance
has a significant impact on the outcome of interest),
stated limitations and information used for risk of bias
assessment (informed by the cited checklists).
A descriptive synthesis of the study information and
risk of bias structured around the perspectives (health,
health system and economic burden) and related methods
used will be provided. This will include a results table con-
taining individual level study data, and summary graphical
representation of study characteristics such as scatter plots
of estimates for excess mortality and monetary cost. We
anticipate limited scope for a meta-analysis given the as-
sumed heterogeneous nature of identified outcomes, stud-
ies included may differ across perspective, infection site,
infection type/causative organism, bug-drug combinations
and sub-populations. However, if there are suitable data
for one drug-bug combination in similar populations, then
forest plots will be constructed utilising hazard ratio as
the comparative outcome [15].
The format of this write-up will be a manuscript which
will be submitted for publication in a peer-reviewed jour-
nal, it will also contribute to the lead reviewer’s (NN) PhD
project as part of the National Institute for Health Re-
search Health Protection Research Unit (NIHR HPRU)
in Healthcare Associated Infections and Antimicrobial
Resistance.
Discussion
Recent estimates for the burden suggest that AMR that
it is a significant economic burden to the global economy
[1], whilst previous reviews have suggested that perhaps
study outcome and methodology impacts whether AMR
is found to have a significant burden or not [8]. Yet, there
has been no literature review which formally looks to as-
sess the quality of such studies.
Originally, the leading author ran a similar search strat-
egy independently; however, after discussion with co-
authors, it was realised that given the nature of previous
reviews, and the lack of quality assessment of previous lit-
erature, the original study design did not adequately an-
swer the research question or fill the current research gap.
Therefore, the original study was halted (results not pub-
lished in peer-review) and the study protocol was revised
into the protocol written here.
This review will provide an overview of previous health,
cost and economic definitions of burden in the context of
AMR. The review will also explore the methods that have
been used to calculate this burden and discuss resulting
study quality. This review can therefore act as a guide to
methods for future research.
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